# A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

> **NCT03764293** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 543 (actual)

## Conditions studied

- Locally Advanced or Metastatic and Unresectable HCC

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** Apatinib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT03764293
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2022-02-08
- **Final completion:** 2023-06-14
- **Target enrollment:** 543 (ACTUAL)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03764293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03764293, "A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03764293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*